Nicotine (Non-Tobacco)
Real cognitive effects, real addiction: the rare record where the side effect is the business model.
C
Evidence grade
C-
Worth it
$15-30/month
Typical cost
DoseResearch doses: transdermal patches delivering 7 to 21 mg/day in impairment trials; gum and pouches at 2 to 4 mg per piece in consumer use. There is no dose this record recommends. Someone determined to use nicotine despite this record should know that slower formats (patch) carry lower dependence liability than fast formats (pouches, vaping), that daily use builds tolerance within weeks, and that 'microdosing' schedules are marketing inventions with no trial behind them.
BasisNicotine forces the question this library exists to answer honestly: what is a real benefit worth when the molecule collects payment in dependence? The cognitive effects are genuine, replicated, and modest.
Nicotine, separated from tobacco and sold as gum, lozenges, and pouches, is marketed as a focus nootropic on the strength of a genuine research literature. We grade Nicotine (Non-Tobacco) C on evidence and C- for worth-it at about $15-30 per month.
What it does
Nicotine, separated from tobacco and sold as gum, lozenges, and pouches, is marketed as a focus nootropic on the strength of a genuine research literature. It is also the addictive agent of the cigarette, in a cleaner vehicle. Both facts are in its name here, and this record refuses to grade either one without the other.
What the research says
Improves attention and some memory measures in meta-analysis, in deprived smokers and non-smokers alike
Evidence: moderate. Heishman 2010 pooled 41 placebo-controlled studies: nicotine improved fine motor performance, alerting attention accuracy and response time, orienting attention, and episodic memory recognition in non-deprived participants. Effect sizes are small to moderate and the literature is real. In mild cognitive impairment, six months of transdermal nicotine (Newhouse 2012) improved attention and memory measures versus placebo. This is a genuinely active cognitive drug, which is exactly why the rest of this record exists.
The dependence profile is the product, and it is not separable from the benefit
Evidence: strong. Nicotine's reinforcing pharmacology is the best documented in addiction science. Delivery speed governs liability: cigarettes are the most addictive format, pouches and gum slower but genuinely dependence-forming in nicotine-naive users, with tolerance, withdrawal (irritability, anxiety, poor concentration, the very deficits users then dose against), and dose escalation. A meaningful share of the 'benefit' regular users feel is withdrawal relief misread as enhancement. Any honest record leads here, so this one does.
Nicotine forces the question this library exists to answer honestly: what is a real benefit worth when the molecule collects payment in dependence? The cognitive effects are genuine, replicated, and modest. The addiction is genuine, replicated, and not modest. C for the pharmacology, with the grade deliberately inseparable from this rationale: read as 'an effective drug whose cost structure disqualifies it as a supplement for the healthy.'
Is it worth it?
Evidence (C) sits below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at C-. About $22 a month for gum or pouches. The money is the smallest cost this product charges; the model's number is printed because the model is the model, and this sentence exists because it is not the whole account. Derived from the October 2026 worth-it model.
Typical cost
$15-30/month
Common form, not a brand recommendation
Dosage context established
Research doses: transdermal patches delivering 7 to 21 mg/day in impairment trials; gum and pouches at 2 to 4 mg per piece in consumer use. There is no dose this record recommends. Someone determined to use nicotine despite this record should know that slower formats (patch) carry lower dependence liability than fast formats (pouches, vaping), that daily use builds tolerance within weeks, and that 'microdosing' schedules are marketing inventions with no trial behind them.
Worth-it leaderboard
Nicotine (Non-Tobacco) sits outside the worth-it top 20.
Nicotine (Non-Tobacco) sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Dependence and withdrawal, covered above, are the primary harms. Additionally: nicotine raises heart rate and blood pressure acutely; long-term replacement-therapy data are comparatively reassuring on cardiovascular events, though use during pregnancy is associated with developmental harms and is not advised. Adolescent exposure is a specific concern given brain development, and consumer pouches are now a youth-uptake story as well as a nootropic one. Nicotine is toxic in concentrated liquid form, a storage hazard around children. Combining with stimulants stacks cardiovascular strain.
Longevity Lab Report
Nicotine (Non-Tobacco) news. Graded when it happens.
The grade on this page stays free. The email carries the news on nicotine (non-tobacco): expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded with the dependence profile at the center, per the queue's instruction for this item. The cognitive evidence is presented in full because understating it would be its own distortion; the record's judgment is that the evidence does not survive contact with the addiction pharmacology for a nicotine-naive reader, and may be a rational specialist conversation for documented cognitive impairment under supervision.
- 2026-10-23|Listed under cognition, matching the graded meta-analytic findings, with the population and dependence limits carried in the record.
The week's longevity and biohacking news.
This grade for Nicotine (Non-Tobacco) rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.